aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Recursion Pharmaceuticals is an American company dedicated to researching, discovering, and developing pharmaceuticals. The company focuses on understanding the interaction of known bioactive compounds with hereditary diseases, aiming to innovate treatments that address these genetic conditions.
Recursion Pharmaceuticals has made significant strides in the pharmaceutical industry, leveraging advanced technologies to accelerate drug discovery and development. Their impactful work has garnered attention and support from notable investors, contributing to advancements in hereditary disease treatments.
Operating Status
Active
Ownership Type(s)
Public, Venture Capital
Main Product(s)
Pharmaceuticals
Technology
AI, Machine Learning
Tags
Biotech, Ai Operations
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
Global
When was Recursion Pharmaceuticals founded?
Recursion Pharmaceuticals was founded in 2013.
Where is Recursion Pharmaceuticals’s headquarters located?
Recursion Pharmaceuticals’s headquarters is located in Salt Lake City, US.
When was Recursion Pharmaceuticals’s last funding round?
Recursion Pharmaceuticals’s most recent funding round was for $50M (USD) in July 2023.
How many employees does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 500 employees as of Feb 6, 2024.
How much has Recursion Pharmaceuticals raised to-date?
As of July 05, 2023, Recursion Pharmaceuticals has raised a total of $665.4M (USD) since Jul 12, 2023.
Add Comparison
Total Raised to Date
$665.4M
USD
Last Update Jul 12, 2023
Last Deal Details
$50M
USD
Jul 12, 2023
Post Ipo Equity
Total Employees Over Time
500
As of Feb 2024
Recursion Pharmaceuticals Address
383 S Colorow Dr
Salt Lake City,
84108
United States
TechCrunch
Granza Bio grabs $7M seed from Felicis and YC to advance delivery of cancer treatments
Ashwin Nandakumar and Ashwin Jainarayanan were working on their doctorates at adjacent departments in Oxford, but they didn’t know each...
Jul 3, 2024
Is this the right Recursion Pharmaceuticals?
Help us improve our AI - Is this article for the right company?
TechCrunch
Enveda raises $55M to combine ancient remedies with AI for drug discovery
For centuries, people chewed willow tree bark to relieve pain, but scientists at chemical firm Bayer didn’t isolate its active ingredient...
Jun 14, 2024
Is this the right Recursion Pharmaceuticals?
Help us improve our AI - Is this article for the right company?
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts